MedTrace Logo

Adenosine-induced Myocardial Blood Flow in Peripheral Artery Disease Patients

NCT02121288 · Status: WITHDRAWN · Phase: PHASE4 · Type: INTERVENTIONAL

Last updated 2014-10-15

No results posted yet for this study

Summary

The purpose of the study is to assess the effect of blood flow to the heart when subjects are treated with ticagrelor (Brilinta) or clopidogrel (antiplatelet drugs that stop the blood from clumping together) in patients with Peripheral Artery Disease (PAD).

Conditions

  • Peripheral Artery Disease
  • Vascular Disease
  • Arterial Occlusion Disease
  • Intermittent Claudication
  • Ankle Brachial Index (0.9 or Less)

Interventions

DRUG

Ticagrelor

Day 1: Loading dose of ticagrelor 180mg (two 90mg tablets) followed by 90mg dose at 12 hours after loading dose. Subject continues to take ticagrelor 90mg twice a day (morning and evening) for 7 days until next visit (Day 7).

DRUG

clopidogrel

Day 1: Clopidogrel 75mg oral tablet. Subjects will continue to take clopidogrel 75mg once a day for 7 days until next visit (Day 7/Visit 3). Note: no loading dose is given for the clopidogrel as those subjects are already on chronic dosing.

Sponsors & Collaborators

Principal Investigators

  • Matthew Budoff, MD · Lundquist Institute for Biomedical Innovation at Harbor-UCLA Medical Center

  • Gabriel Vorobiof, MD · University of California, Los Angeles

Study Design

Allocation
RANDOMIZED
Purpose
TREATMENT
Masking
NONE
Model
PARALLEL

Eligibility

Min Age
18 Years
Max Age
59 Years
Sex
ALL
Healthy Volunteers
No

Timeline & Regulatory

Start
2014-12-31
Primary Completion
2016-02-29
Completion
2016-02-29

More Related Trials

Entities

Diseases
Companies

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT02121288 on ClinicalTrials.gov